Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityRobert M. Campbell, Xiang S. Ye, Bryan D. Anderson et al.|Molecular Cancer Therapeutics|2013Cited by 121
IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated DiseaseKirk A. Staschke, Songqing Na, Sucai Dong et al.|The Journal of Immunology|2009Cited by 55
Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)Nathan A. Brooks, Raymond Gilmour, ZhaoHai Lu et al.|Cancer Research|2019Cited by 11
Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)Vivian Salama, Marina Konopleva, Nathan A. Brooks et al.|Cancer Research|2020Cited by 8
Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.Megan N. Thobe, Richard A. Walgren, S. Betty Yan et al.|Cancer Research|2013Cited by 3